<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942017000100003</article-id>
<article-id pub-id-type="doi">10.30827/ars.v58i1.5917</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Intervenciones Farmaceuticas en pacientes con Diabetes Mellitus Tipo 2]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmaceutical interventions in patients with Type 2 Diabetes Mellitus]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maidana]]></surname>
<given-names><![CDATA[Gladys Mabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zully]]></surname>
<given-names><![CDATA[Vera]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Samaniego]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mastroianni]]></surname>
<given-names><![CDATA[Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lugo]]></surname>
<given-names><![CDATA[Gladys Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,U.N.A Facultad de Ciências Químicas ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade Estadual Paulista, UNESP Faculdade de Ciências Farmacêuticas Departamento de Fármacos e Medicamentos]]></institution>
<addr-line><![CDATA[Araraquara SP]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2017</year>
</pub-date>
<volume>58</volume>
<numero>1</numero>
<fpage>21</fpage>
<lpage>28</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942017000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942017000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942017000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: La Atención Farmacêutica es la provision responsable de la farmacoterapia con el propósito de alcanzar resultados concretos que mejoren la calidad de vida de los pacientes.  Objetivo: Evaluar el impacto de las intervenciones farmacéuticas en pacientes con Diabetes Mellitus Tipo 2.  Metodologia: Ensayo Clínico Aleatorizado, con medición de variables antes y después. No probabilísti-co. De conveniencia. Participaron 32 pacientes del grupo intervenido y 32 en grupo control. Se realizaron entrevistas mensuales en un periodo de intervención farmacéutica de 6 meses (desde octubre 2011 hasta junio 2012). Se registraron solo 3 abandonos.  Resultados: La edad de los pacientes fue 55,6±10,6 anos. Los pacientes del grupo intervenido mejoraron la glicemia en 34%, donde 24 pacientes tenian el valor (&lt; 130 mg/dL); la hemoglobina glicosilada mejoró 1,9%, donde 15 pacientes lograron los parámetros deseados (&lt; 6,5%). La calidad de vida del grupo inter-venido aumentó de (56,3 a 71,3 %) y fue medido con el cuestionario SF-36. En el grupo intervenido se encontraron 80 problemas relacionados con medicamentos, en 27 pacientes, se resolvieron 59; al final del estudio 12 pacientes resolvieron todos los problemas relacionados con medicamentos; se realizaron 254 intervenciones farmacêuticas, el nivel de conocimiento de los pacientes sobre la enfermedad mejoró en 41%, el conocimiento sobre sus medicamentos mejoró en 53%.  Conclusión: Las intervenciones farmacêuticas mejoraron los parámetros clínicos de glicemia, hemoglobina glicosilada, optimizaron el uso de medicamentos, disminuyeron los problemas relacionados con medicamentos, mejoraron la calidad de vida de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Pharmaceutical Care is the responsible provision of the pharmacotherapy with the purpose of achieving concrete results in order to improve the quality of life of the patients.  Objective: To evaluate the impact of pharmaceutical intervention on patients with Type 2 Diabetes Mellitus.  Methodology: Random Clinical Assay with measurement of variables before and after. Non probabilistic. At convenience. Participating population was composed of 32 patients at the intervention group and 32 at the control group. Monthly interviews were performed in a period of pharmaceutical intervention of 6 months (from October 2011 to June 2012). In this period they were recorded only 3 dropouts.  Results: The patients&#8217; age was 55.6 ± 10.6 years. Patients in the intervention group improved glycaemia in 34%, where 24 patients had the value (&lt; 130 mg / dL); the glycosylated hemoglobin improved 1.9%, where 15 patients achieved the desired parameters (&lt; 6.5%). The quality of life of the intervention group increased from (56.3 to 71.3%) and was measured with the SF-36 questionnaire. In the intervened group, 80 drug-related problems were found; in 27 patients, 59 were resolved; at the end of the study 12 patients resolved all drug-related problems; 254 pharmaceutical interventions were performed, the level of patient knowledge about the disease improved by 41%, knowledge about their medications improved by 53%.  Conclusion: Pharmaceutical interventions improved the clinical parameters of glycemia, glycosylated hemoglobin, optimized drug use, decreased drug-related problems, and improved the quality of life of patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Intervención Farmacéutica]]></kwd>
<kwd lng="es"><![CDATA[Atención Farmacéutica]]></kwd>
<kwd lng="es"><![CDATA[Diabetes Mellitus Tipo 2]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceutical Intervention]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceutical Care]]></kwd>
<kwd lng="en"><![CDATA[Type 2 Diabetes Mellitus]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Nota Descriptiva OMS N°312, Septiembre 2012 datos de la situación mundial de la Diabetes]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Primera Encuesta Nacional de Factores de Riesgo para Enfermedades No Trasmisibles]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Paraguay ]]></publisher-loc>
<publisher-name><![CDATA[OPS-OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Standards of medical care in diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2011</year>
<volume>34</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S11-61</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gardete Correia]]></surname>
<given-names><![CDATA[l]]></given-names>
</name>
<name>
<surname><![CDATA[Fragoso de Almeida]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Massano Cardoso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dores]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sequeira Duarte]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Duarte]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetes: Factos e Números 2012]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Sociedade Portuguesa de Diabetología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Faus Dáder]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Romero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La atención farmacêutica en farmacia comunitaria:evolución de conceptos, necesidades de formación, modalidades y estrategias para su puesta en marcha]]></article-title>
<source><![CDATA[Pharm Care Esp]]></source>
<year>1999</year>
<volume>1</volume>
<page-range>52-61</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strand]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Morley]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Cipolle]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lamsam]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-related problems: theirs structure and function]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>1990</year>
<volume>24</volume>
<page-range>1093-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>Grupo de Investigación en Atención Farmacêutica (CTS-131). Universidad de Granada</collab>
<collab>Grupo de Investigación en Farmacología Aplicada y Farmacoterapia (CTS-259). Universidad de Sevilla</collab>
<collab>Grupo de Investigación en Farmacologia de Productos Naturales (CTS-164). Universidad de Granada</collab>
<article-title xml:lang=""><![CDATA[Segundo Consenso de Granada sobre Problemas Relacionados con Medicamentos]]></article-title>
<source><![CDATA[Ars Pharmaceutica]]></source>
<year>2002</year>
<volume>43</volume>
<page-range>175-84</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ernst]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grizzle]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug-related morbidity and mortality:updating the cost-of-illness model]]></article-title>
<source><![CDATA[J Am Pharm Assoc]]></source>
<year>2001</year>
<volume>41</volume>
<page-range>192-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morgado]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Morgado]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Castelo-Branco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy:Review and meta-analysis]]></article-title>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2011</year>
<volume>68</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>241-53</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salgado]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Moles]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Benrimoj]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez-Llimos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacists'interventions in the management of patients with chronic kidney disease:a systematic review]]></article-title>
<source><![CDATA[Nephrol Dial Transplant]]></source>
<year>2012</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>276-92</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simpson]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Biggs]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practice-Based Research:Lessons from Community Pharmacist Participants]]></article-title>
<source><![CDATA[Pharmacotherapy]]></source>
<year>2001</year>
<volume>21</volume>
<page-range>731-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strand]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Morley]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Cipolle]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lamsam]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Problemas relacionados con el medicamento:su estructura y función]]></article-title>
<source><![CDATA[Pharm Care Esp]]></source>
<year>1999</year>
<page-range>127-32</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Antó]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La versión espanola del SF-36 Health Survey (Cuestionario de Salud SF-36):un instrumento para la medida de los resultados clínicos]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>1995</year>
<volume>104</volume>
<page-range>771-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canales]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Canales]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Elia]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Metodología de la investigación: Manual para el desarrollo de personal de salud]]></source>
<year>2005</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[OPS/OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lugo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bittner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pêrez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Implementación de un Programa de Atención Farmacêutica en Farmacias Co-munitarias para la detección de la Hipertensión Arterial y suSeguimiento Farmacoterapéutico]]></article-title>
<source><![CDATA[Lat. Am. J. Pharm]]></source>
<year>2007</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>590-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<collab>UK Prospective Diabetes Study Group</collab>
<article-title xml:lang=""><![CDATA[Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:(UKPDS 38)]]></article-title>
<source><![CDATA[Rev. British Medical Journal]]></source>
<year>1999</year>
<volume>317</volume>
<page-range>703-13</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iyer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Coderre]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mckelvey]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moore]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An employer-based, pharmacist intervention model for patients with type 2 diabetes]]></article-title>
<source><![CDATA[Am J Health Syst Pharm]]></source>
<year>2015</year>
<volume>67</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>312-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lores Delgado]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lazo Roblejo]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zúniga Moro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bermúdez Camps]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seguimiento farmacoterapéutico de pacientes con insuficiencia cardiaca congestiva dispensados en la farmacia Principal Municipal Santiago de Cuba]]></article-title>
<source><![CDATA[Pharm Care Esp]]></source>
<year>2011</year>
<volume>13</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>114-22</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vázquez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Chacón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Espejo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Faus]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resultados del seguimiento farmacoterapéutico en una farmacia comunitaria]]></article-title>
<source><![CDATA[Seguim Farmacoter]]></source>
<year>2004</year>
<volume>2</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>189-94</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cioffi]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Caron]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Kalus]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glycosylated haemoglobin, cardiovascular, and renal outcomes in a pharmacistmanaged clinic]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2004</year>
<volume>38</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>771-5</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wermeille]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bennie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Mcknight]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmaceutical care model for patients with type 2 diabetes: Integration of the community pharmacist into the diabetes team-a pilot study]]></article-title>
<source><![CDATA[Pharm World Sci]]></source>
<year>2004</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-25</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gastelurrutia]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez Llimos]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Delgado]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gastelurrutia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Faus]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Benrimoj]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Barriers and facilitators to the disseminaton and implementation of cognitive services in Spanish community pharmacies]]></article-title>
<source><![CDATA[Seguim Farmac]]></source>
<year>2005</year>
<volume>3</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>65-77</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fornos Pérez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés Rodríguez]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés Iglesias]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra Garcia]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Egea Ibernon]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain]]></article-title>
<source><![CDATA[Pharm World Sci]]></source>
<year>2006</year>
<volume>28</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>65-72</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vivian]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pharmacist's role in maintaining adherence to insulin therapy in type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Consult Pharm]]></source>
<year>2007</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>320-32</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dizaji]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Taghdisi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Solhi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hoseini]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Shafieyan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Qorbani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of educational intervention based on Precede model on self care behaviors and control in patients with type 2 diabetes in 2012]]></article-title>
<source><![CDATA[Journal of Diabetes &amp; Metabolic Disorders]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baena]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Fajardo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Olmos]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Calleja]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cumplimiento, conocimiento, y automedicación como factores asociados a los resultados clínicos negativos de la farmacoterapia]]></article-title>
<source><![CDATA[Ars Pharm]]></source>
<year>2005</year>
<volume>46</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>365-81</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fornos Pérez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés Rodríguez]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Guerra García]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diseño y validación de un cuestionario de conocimiento sobre diabetes en pacientes de farmacia comunitaria]]></article-title>
<source><![CDATA[Pharm Care Esp]]></source>
<year>2003</year>
<volume>5</volume>
<page-range>268-74</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Testa]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mejorar la terapia de diabetes: aumentar la satisfacción]]></article-title>
<source><![CDATA[Diabetes Voice]]></source>
<year>2003</year>
<volume>48</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>5</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bajcar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Guzzo]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Einarson]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sensitivity of patient outcomes to pharmacist interventions. Part I:systematic review and metaanalysis in diabetes management]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2007</year>
<volume>41</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1566-82</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fornos Pérez]]></surname>
<given-names><![CDATA[J.A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernandez Cordeiro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[García Rodríguez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Anón]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés Iglesias]]></surname>
<given-names><![CDATA[J.C]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés Rodríguez]]></surname>
<given-names><![CDATA[N.F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of the use of medication for diabetic patients in the province of Pontevedra]]></article-title>
<source><![CDATA[Av. Diabetol]]></source>
<year>2010</year>
<volume>26</volume>
<page-range>47-52</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fornos Pérez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[García Rodríguez]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Cordeiro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[González Anón]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés Rodríguez]]></surname>
<given-names><![CDATA[NF]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del conocimiento, el cumplimiento y la satisfacción del tratamiento en pacientes diabéticos en la oficina de farmacia]]></article-title>
<source><![CDATA[Av. Diabetol]]></source>
<year>2008</year>
<volume>24</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>399-406</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarez Guisasola]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[ToféPovedano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Krishnarajh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lyu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mavros]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus:findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2008</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-32</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
